INFANT IBUPROFEN RECALL

Drug Company Tris Pharma has issued a voluntarily recall on infant painkiller from three stores: CVS, Walmart, and Family Dollar. The company recalled “Concentrated Oral Suspension, USP (NSAID), 50 mg per 1.25 mL” sold in 0.5 ounce bottles. Tris Pharma believes the liquid medication could contain more concentrated amounts of ibuprofen. Because they can be […]

Read More

Could Your Birth Control be Hurting You?

Essure, the only FDA-approved permanent contraception device for women, is getting a closer look from the FDA after multiple complaints from users. The product, manufactured by Bayer, is a soft, flexible metal spring inserted into each fallopian tube. Over the course of several months, scar tissue forms around the coils, blocking the tubes to prevent […]

Read More

Mississippi Yaz Injury Lawyer

The drugs Yaz, Yasmin, and Ocella are oral contraceptives that have raised some serious health concerns recently for millions of women taking them. Some of danderous effects that have been linked to Yaz, Yasmin, and Ocella are: Stroke Heart Attack Blood Clots in Lungs-Pulmonary Embolism Blood Clots in Legs-Deep Vein Thrombosis (DVT) Gallbladder Disease Pancreatitis Sudden […]

Read More

Pioglitazone Actos Bladder Cancer Information

In August 2011, the FDA published this Drug Safety Communication about adding safety information about Bladder Cancer to the label of drugs containing Pioglitazone.  The following drugs contain Pioglitazone: Actos, Actoplus Met, Actoplus Met XR, Duetact. The F.D. A. stated the following in the communication: “The U.S. Food and Drug Administration (FDA) is informing the public that […]

Read More

F.D.A. Actos Update

In June, the FDA published this FDA Drug Safety Communication related to the use of the drug Actos and Actos Combinations.  In the Communication, the FDA stated the following: “The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with […]

Read More